9.89
+0.03(+0.30%)
Currency In USD
| Previous Close | 9.86 |
| Open | 9.63 |
| Day High | 10.07 |
| Day Low | 9.61 |
| 52-Week High | 56.93 |
| 52-Week Low | 4.64 |
| Volume | 67,152 |
| Average Volume | 143,609 |
| Market Cap | 121.2M |
| PE | -2.08 |
| EPS | -4.76 |
| Moving Average 50 Days | 8.93 |
| Moving Average 200 Days | 9.35 |
| Change | 0.03 |
If you invested $1000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, it would be worth $179.07 as of September 09, 2025 at a share price of $9.89. Whereas If you bought $1000 worth of Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares 5 years ago, it would be worth $135.11 as of September 09, 2025 at a share price of $9.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
GlobeNewswire Inc.
Jul 30, 2025 12:00 PM GMT
NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical s
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
GlobeNewswire Inc.
Jun 30, 2025 12:00 PM GMT
No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancerData update on schedule for later thi